CYP2C19
Genedrive, U of Manchester Collaborate to Further Validate CYP2C19 Test
Genedrive's CYP2C19 ID Kit will be evaluated by multiple stakeholders in a program funded by Innovate UK and the UK Innovation Accelerator.
UK's NICE Recommends Genetic Testing for Therapy Selection in Stroke Patients
Clopidogrel is less effective at preventing subsequent strokes in patients with certain variations in the CYP2C19 gene and testing could aid treatment selection.
Genomadix Gets FDA 510(k) Clearance for PCR System, CYP2C19 Test
Canada's Genomadix, formerly known as Spartan Bioscience, expects to now commercialize the system and test in the US to guide therapy decisions.
As part of the program, point-of-care tests sold by Genedrive and Genomadix will be assessed, as well as laboratory-developed tests used within the UK National Health Service.
Spartan Bioscience Taps Cardinal Health as US Distributor of CYP2C19 Genotyping Assay
The new distribution partnership is for the US acute care market where, until now, Spartan was selling directly.
Jun 4, 2019